Ameet Sarpatwari

Jul 5, 2024 | onlinelibrary.wiley.com | Junyi Wang |Ameet Sarpatwari |Aaron S. Kesselheim |William B. Feldman

CONFLICT OF INTEREST STATEMENT William B. Feldman reports serving as a consultant for Alosa Health and as an expert witness in litigation against inhaler manufacturers. Supporting Information Filename Description pbc31158-sup-0001-SuppMat.docx34.9 KB Supporting Information REFERENCES 1 Medicare Payment Advisory Commission. Report to Congress: overview of the 340B Drug Pricing Program. MEdpAC; May 2015. Accessed September 20, 2023.

Feb 22, 2024 | jamanetwork.com | Ameet Sarpatwari |S. Tu |Aaron S. Kesselheim

Certain prescription drugs are associated with harms that the US Food and Drug Administration (FDA) concludes can be mitigated with safeguards, such as laboratory testing or prescriber and patient education. For these drugs, the FDA may require manufacturers to implement risk evaluation and mitigation strategies (REMS) encompassing such measures.1 Some manufacturers have obtained patents on these REMS, which provide 20 years of market exclusivity and can frustrate generic competition.

Feb 20, 2024 | ascpt.onlinelibrary.wiley.com | Ameet Sarpatwari |Zhigang Lu |Massimiliano Russo |Heidi Zakoul

CONFLICT OF INTEREST A.S. reports having served as an expert witness for the ACLU on REMS-related litigation concerning mifepristone. A.S.K. served as an expert witness on behalf of a class of individual plaintiffs in a case against Gilead related to its tenofovir-containing products and in a case against GSK related to marketing of Avandia. Supporting Information Filename Description cpt3189-sup-0001-AppendixS1.docxWord 2007 document , 138.3 KB Appendix S1.

Oct 24, 2023 | acpjournals.org | Catherine Hwang |Aaron S. Kesselheim |Ameet Sarpatwari |Krista F Huybrechts

Authors: Catherine S. Hwang, MD, MSPH; Aaron S. Kesselheim, MD, JD, MPH; Ameet Sarpatwari, PhD, JD; Krista F. Huybrechts, MS, PhD; Gregory Brill, MS; Benjamin N. Rome, MD, MPHAffiliations: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts (C.S.H., A.S.K., A.S., K.F.H., G.B., B.N.R.). Disclaimer: Drs.

Mar 6, 2023 | journals.plos.org | Beatrice Brown |Aaron S. Kesselheim |Ameet Sarpatwari

Loading metrics Open Access Policy Forum Policy Forum Policy Forum articles provide a platform for health policy makers from around the world to discuss the challenges and opportunities in improving health care to their constituencies. See all article types » Citation: Brown BL, Kesselheim AS, Sarpatwari A (2023) Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures. PLoS Med 20(3): e1004190.